What is Orca Bio?
Orca Bio operates at the intersection of advanced immunology and precision manufacturing. The company is a late-stage biotechnology enterprise dedicated to the development of high-precision cell therapies. Its core innovation lies in a sophisticated manufacturing platform that utilizes single-cell precision to engineer personalized products. These therapies are intended to replace a patient's diseased blood and immune system with a healthy, functional counterpart, effectively offering a curative approach to complex pathologies. By focusing on allogeneic cell therapy, Orca Bio is positioning itself to redefine standard-of-care protocols for patients suffering from life-threatening blood cancers and severe autoimmune conditions, moving beyond traditional pharmaceutical interventions toward a more precise, biological restoration model.
How much funding has Orca Bio raised?
Orca Bio has raised a total of $442M across 2 funding rounds:
Series D
$192M
Series F
$250M
Series D (2020): $192M with participation from ND Capital, Mubadala, Lightspeed Venture Partners, DCVC Management Co LLC, and 8VC
Series F (2026): $250M led by Lightspeed Venture Partners
Key Investors in Orca Bio
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, consumer, fintech, and infrastructure, partnering with founders from seed through IPO/M&A.
Mubadala
Mubadala is a global investment company based in Abu Dhabi with a mandate to create sustainable financial returns and further the objective of a globally integrated and diversified economy.
8VC
8VC is a venture capital firm that focuses on building and investing in companies that solve fundamental problems in various industries, often leveraging deep technology and data-driven approaches.
What's next for Orca Bio?
With the successful closure of this latest financing, Orca Bio is well-positioned to advance its clinical programs through the final stages of regulatory approval and commercial readiness. The strategic allocation of these funds will likely prioritize the expansion of its manufacturing capabilities to meet anticipated demand for its curative therapies. Furthermore, the company is expected to deepen its research into the scalability of its platform, ensuring that the high-precision nature of its products can be maintained at a commercial scale. As the firm transitions from a development-focused entity to a potential market-ready provider, the focus will shift toward clinical trial milestones and the establishment of a robust supply chain capable of supporting global patient access to its transformative medical solutions.
See full Orca Bio company page
